Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonalcoholic Steatohepatitis.

Brian P Mulhall1, Zobair M Younossi

  • 1Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA.

Current Treatment Options in Gastroenterology
|November 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Food inequity and insecurity and MASLD: burden, challenges, and interventions.

Nature reviews. Gastroenterology & hepatology·2024
Same author

Estimating the economic impact of comorbidities in patients with MASH and defining high-cost burden in patients with noncirrhotic MASH.

Hepatology communications·2024
Same author

The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease.

JHEP reports : innovation in hepatology·2024
Same author

Liver Transplantation Profile Among Teenagers in the United States.

The Journal of adolescent health : official publication of the Society for Adolescent Medicine·2024
Same author

The burden of metabolic dysfunction-associated steatotic liver disease and viral hepatitis in Saudi Arabia.

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association·2024
Same author

Review article: Hepatic steatosis and its associations with acute and chronic liver diseases.

Alimentary pharmacology & therapeutics·2024
Same journal

Esophageal Disorders in the Older Adult.

Current treatment options in gastroenterology·2025
Same journal

Endobariatrics: a Still Underutilized Weight Loss Tool.

Current treatment options in gastroenterology·2023
Same journal

Management of Post Ablative Barrett's Esophagus: a Review of Current Practices and Look at Emerging Technologies.

Current treatment options in gastroenterology·2023
Same journal

Inflammatory Bowel Disease Therapy and Venous Thromboembolism.

Current treatment options in gastroenterology·2023
Same journal

Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment.

Current treatment options in gastroenterology·2023
Same journal

Celiac Disease in the Elderly.

Current treatment options in gastroenterology·2023
See all related articles

Nonalcoholic steatohepatitis (NASH) is a serious liver condition with increasing incidence. Current treatments aim to manage contributing factors like insulin resistance and inflammation, but no single therapy is universally effective yet.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Nonalcoholic steatohepatitis (NASH) is a significant public health concern due to its rising prevalence.
  • NASH involves liver inflammation and damage beyond simple fat accumulation, potentially leading to cirrhosis.
  • Key contributing factors include insulin dysregulation, lipid deposition, and oxidative stress.

Purpose of the Study:

  • To review the current understanding of Nonalcoholic steatohepatitis (NASH) pathophysiology.
  • To outline current therapeutic strategies for managing NASH.
  • To highlight promising, though not yet conclusive, treatment approaches.

Main Methods:

  • Literature review of Nonalcoholic steatohepatitis (NASH) research.
  • Analysis of contributing factors to hepatic injury.

Related Experiment Videos

  • Evaluation of current and emerging treatment protocols.

    • Main Results:

    • NASH progression is characterized by hepatocyte injury, including ballooning degeneration and fibrosis.
    • Multiple insults, such as metabolic dysfunction and oxidative stress, drive NASH.
    • Existing treatments target insulin imbalance, lipids, and inflammation, with variable success.

    Conclusions:

    • Nonalcoholic steatohepatitis (NASH) requires histologic confirmation and addresses complex contributing factors.
    • While current interventions show promise, definitive and universally effective therapies are still under investigation.
    • Further research is needed to establish conclusive treatments for NASH.